UBS Group’s Proshares UltraPro NASDAQ Biotechnology UBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-55
| Closed | -$2K | – | 8775 |
|
|
2019
Q4 | $2K | Sell |
55
-7
| -11% | -$186 | ﹤0.01% | 7903 |
|
|
2019
Q3 | $1K | Sell |
62
-2,128
| -97% | -$47.8K | ﹤0.01% | 7918 |
|
|
2019
Q2 | $57K | Buy |
+2,190
| New | +$54K | ﹤0.01% | 5810 |
|
|
2018
Q4 | – | Sell |
-3,269
| Closed | -$144K | – | 8503 |
|
|
2018
Q3 | $144K | Buy |
3,269
+1,224
| +60% | +$49.4K | ﹤0.01% | 5290 |
|
|
2018
Q2 | $68K | Buy |
+2,045
| New | +$63.7K | ﹤0.01% | 5755 |
|
|
2018
Q1 | – | Sell |
-3,003
| Closed | -$101K | – | 8377 |
|
|
2017
Q4 | $101K | Buy |
+3,003
| New | +$103K | ﹤0.01% | 5344 |
|
|
2017
Q2 | – | Sell |
-2,651
| Closed | -$73K | – | 8183 |
|
|
2017
Q1 | $73K | Buy |
+2,651
| New | +$69.8K | ﹤0.01% | 5266 |
|
|
2016
Q4 | – | Sell |
-2,622
| Closed | -$76K | – | 8193 |
|
|
2016
Q3 | $76K | Buy |
2,622
+1,666
| +174% | +$47.4K | ﹤0.01% | 5182 |
|
|
2016
Q2 | $20K | Sell |
956
-4,969
| -84% | -$126K | ﹤0.01% | 6322 |
|
|
2016
Q1 | $140K | Buy |
5,925
+5,385
| +997% | +$149K | ﹤0.01% | 4737 |
|
|
2015
Q4 | $31K | Buy |
540
+150
| +38% | +$7.94K | ﹤0.01% | 6310 |
|
|
2015
Q3 | $17K | Buy |
+390
| New | +$31.6K | ﹤0.01% | 6873 |
|
Other funds holding UBIO
UBS Group's UBIO Position: Q1 2020 in Review
UBS Group sold out of Proshares UltraPro NASDAQ Biotechnology (UBIO) in Q1 2020, closing a stake of 55 shares — an estimated $2K sold.
UBS Group first reported a position in UBIO in Q3 2015 and held it in 12 quarters. The position peaked at $144K in Q3 2018. 1 fund tracked by Wall St. Rank holds UBIO as of Q1 2020.
- UBS Group reported no remaining Proshares UltraPro NASDAQ Biotechnology position as of Q1 2020 after selling out during the quarter.
- UBS Group sold 55 Proshares UltraPro NASDAQ Biotechnology shares in Q1 2020, an estimated $2K.
- UBS Group first reported a position in Proshares UltraPro NASDAQ Biotechnology in Q3 2015 and held it in 12 quarters.
- UBS Group's Proshares UltraPro NASDAQ Biotechnology position peaked at $144K in Q3 2018.
- 1 fund tracked by Wall St. Rank held Proshares UltraPro NASDAQ Biotechnology as of Q1 2020.
Based on UBS Group's 13F filing for Q1 2020, filed 1 May 2020.